Strategic Global Investments, Inc.
Strategic Global Investments, Inc. (STBV) Stock Competitors & Peer Comparison
See (STBV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STBV | $0.00 | +0.00% | 471 | N/A | -$0.14 | N/A |
| BMXXY | $7.95 | -0.87% | 9.4B | 20.38 | $0.39 | +1.30% |
| EBOSY | $26.42 | +0.00% | 1.4B | 17.97 | $1.47 | +5.42% |
| AVNBF | $24.70 | +0.00% | 724M | 72.65 | $0.34 | +1.00% |
| EBRCZ | $0.42 | +0.00% | 316.1M | -3.53 | -$0.12 | N/A |
| XVIPY | $6.54 | +0.00% | 206M | N/A | N/A | N/A |
| TRXDW | $0.15 | -11.76% | 40.1M | N/A | N/A | N/A |
| ACIXF | $0.03 | -3.55% | 33.6M | -2.99 | -$0.01 | N/A |
| NVNBW | $0.01 | +0.00% | 141.5K | -0.00 | -$1.95 | N/A |
| GWPC | $0.00 | +0.00% | 52K | -0.01 | -$0.01 | N/A |
Stock Comparison
STBV vs BMXXY Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, BMXXY has a market cap of 9.4B. Regarding current trading prices, STBV is priced at $0.00, while BMXXY trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 20.38. In terms of profitability, STBV's ROE is -1.13%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, STBV is more volatile compared to BMXXY. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check BMXXY's competition here
STBV vs EBOSY Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, EBOSY has a market cap of 1.4B. Regarding current trading prices, STBV is priced at $0.00, while EBOSY trades at $26.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas EBOSY's P/E ratio is 17.97. In terms of profitability, STBV's ROE is -1.13%, compared to EBOSY's ROE of +0.06%. Regarding short-term risk, STBV is more volatile compared to EBOSY. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check EBOSY's competition here
STBV vs AVNBF Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, AVNBF has a market cap of 724M. Regarding current trading prices, STBV is priced at $0.00, while AVNBF trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas AVNBF's P/E ratio is 72.65. In terms of profitability, STBV's ROE is -1.13%, compared to AVNBF's ROE of +0.05%. Regarding short-term risk, STBV is more volatile compared to AVNBF. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check AVNBF's competition here
STBV vs EBRCZ Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, EBRCZ has a market cap of 316.1M. Regarding current trading prices, STBV is priced at $0.00, while EBRCZ trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas EBRCZ's P/E ratio is -3.53. In terms of profitability, STBV's ROE is -1.13%, compared to EBRCZ's ROE of -329.75%. Regarding short-term risk, STBV is more volatile compared to EBRCZ. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check EBRCZ's competition here
STBV vs XVIPY Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, XVIPY has a market cap of 206M. Regarding current trading prices, STBV is priced at $0.00, while XVIPY trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas XVIPY's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to XVIPY's ROE of +0.01%. Regarding short-term risk, STBV is more volatile compared to XVIPY. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check XVIPY's competition here
STBV vs TRXDW Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, TRXDW has a market cap of 40.1M. Regarding current trading prices, STBV is priced at $0.00, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas TRXDW's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to TRXDW's ROE of -1.18%. Regarding short-term risk, STBV is more volatile compared to TRXDW. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check TRXDW's competition here
STBV vs ACIXF Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, ACIXF has a market cap of 33.6M. Regarding current trading prices, STBV is priced at $0.00, while ACIXF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas ACIXF's P/E ratio is -2.99. In terms of profitability, STBV's ROE is -1.13%, compared to ACIXF's ROE of -1.04%. Regarding short-term risk, STBV is more volatile compared to ACIXF. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check ACIXF's competition here
STBV vs NVNBW Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, NVNBW has a market cap of 141.5K. Regarding current trading prices, STBV is priced at $0.00, while NVNBW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas NVNBW's P/E ratio is -0.00. In terms of profitability, STBV's ROE is -1.13%, compared to NVNBW's ROE of -0.61%. Regarding short-term risk, STBV is more volatile compared to NVNBW. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check NVNBW's competition here
STBV vs GWPC Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, GWPC has a market cap of 52K. Regarding current trading prices, STBV is priced at $0.00, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas GWPC's P/E ratio is -0.01. In terms of profitability, STBV's ROE is -1.13%, compared to GWPC's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to GWPC. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check GWPC's competition here
STBV vs SXHHF Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, SXHHF has a market cap of 38.1K. Regarding current trading prices, STBV is priced at $0.00, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, STBV's ROE is -1.13%, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, STBV is less volatile compared to SXHHF. This indicates potentially lower risk in terms of short-term price fluctuations for STBV.Check SXHHF's competition here
STBV vs DGCRF Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, DGCRF has a market cap of 21.5K. Regarding current trading prices, STBV is priced at $0.00, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas DGCRF's P/E ratio is 0.00. In terms of profitability, STBV's ROE is -1.13%, compared to DGCRF's ROE of -1.11%. Regarding short-term risk, STBV is less volatile compared to DGCRF. This indicates potentially lower risk in terms of short-term price fluctuations for STBV.Check DGCRF's competition here
STBV vs KKUR Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, KKUR has a market cap of 8.2K. Regarding current trading prices, STBV is priced at $0.00, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas KKUR's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to KKUR's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to KKUR. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check KKUR's competition here
STBV vs SCIE Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, SCIE has a market cap of 4.9K. Regarding current trading prices, STBV is priced at $0.00, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas SCIE's P/E ratio is -0.00. In terms of profitability, STBV's ROE is -1.13%, compared to SCIE's ROE of +0.51%. Regarding short-term risk, STBV is more volatile compared to SCIE. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check SCIE's competition here
STBV vs OMRX Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, OMRX has a market cap of 4.7K. Regarding current trading prices, STBV is priced at $0.00, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas OMRX's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to OMRX's ROE of -0.15%. Regarding short-term risk, STBV is less volatile compared to OMRX. This indicates potentially lower risk in terms of short-term price fluctuations for STBV.Check OMRX's competition here
STBV vs IBXG Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, IBXG has a market cap of 2K. Regarding current trading prices, STBV is priced at $0.00, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas IBXG's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to IBXG's ROE of N/A. Regarding short-term risk, STBV and IBXG have similar daily volatility (163.64).Check IBXG's competition here
STBV vs DMSI Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, DMSI has a market cap of 1.9K. Regarding current trading prices, STBV is priced at $0.00, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas DMSI's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to DMSI's ROE of -0.32%. Regarding short-term risk, STBV is more volatile compared to DMSI. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check DMSI's competition here
STBV vs AAXT Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, AAXT has a market cap of 1.6K. Regarding current trading prices, STBV is priced at $0.00, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas AAXT's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, STBV is more volatile compared to AAXT. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check AAXT's competition here
STBV vs XCRP Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, XCRP has a market cap of 1.5K. Regarding current trading prices, STBV is priced at $0.00, while XCRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas XCRP's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to XCRP's ROE of -3.49%. Regarding short-term risk, STBV is more volatile compared to XCRP. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check XCRP's competition here
STBV vs BMGP Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, BMGP has a market cap of 1.3K. Regarding current trading prices, STBV is priced at $0.00, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas BMGP's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to BMGP's ROE of -0.50%. Regarding short-term risk, STBV and BMGP have similar daily volatility (163.64).Check BMGP's competition here
STBV vs IMRSQ Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, IMRSQ has a market cap of 626. Regarding current trading prices, STBV is priced at $0.00, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, STBV and IMRSQ have similar daily volatility (163.64).Check IMRSQ's competition here
STBV vs OMDD Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, OMDD has a market cap of 310. Regarding current trading prices, STBV is priced at $0.00, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas OMDD's P/E ratio is N/A. In terms of profitability, STBV's ROE is -1.13%, compared to OMDD's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to OMDD. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check OMDD's competition here
STBV vs QMED Comparison May 2026
STBV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STBV stands at 471. In comparison, QMED has a market cap of 17. Regarding current trading prices, STBV is priced at $0.00, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STBV currently has a P/E ratio of N/A, whereas QMED's P/E ratio is -0.00. In terms of profitability, STBV's ROE is -1.13%, compared to QMED's ROE of N/A. Regarding short-term risk, STBV is more volatile compared to QMED. This indicates potentially higher risk in terms of short-term price fluctuations for STBV.Check QMED's competition here